Insulin therapy is no cheaper than thiazolidinedione therapy in patients with type 2 diabetes

British Columbia Medical Journal

Volumn 48, Issue 8, 2006, Pages 392-398

  Aydin, Cristina M ^a   Taylor, Richard ^a   Billington, Emma O ^a   Tildesley, Hugh D ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845245596     PISSN: 00070556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Meltzer S, Leiter L, Daneman D, et al. Clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ 1998; 159(suppl):S1-S29.
2. Goldstein, BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002;90(suppl):3G-10G.
3. Gerber P, Lubben G, Heusler S, et al. Effects of pioglitazone on metabolic control and blood pressure: A randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003;19: 532-539.
4. Poulsen MK, Henriksen JE, Hother-Nielsen O, et al. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003;26: 3273-3279.
5. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2002; 25(suppl 1):28-32.
6. Stratton IM, Adler Al, Neil HAW, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-412.
7. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27(suppl 2):s18-s21.
8. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27(suppl 2):s37-s43.
9. Schoonjans K, Auwerx J. Thiazolidinediones: An update. Lancet 2000;355: 1008-1010.
10. Parulkar A, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
11. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-508.
12. Goke B, Lubben G, Bates PC. Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose. Exp Clin Endocrinol Diabetes 2004;112:115-117
13. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021-1029.
14. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:1637-1645.
15. Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58:192-200.
16. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-2104.
17. Ceriello A, Johns D, Widel M, et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005;28:266-272.
18. Dailey GE 3rd, Noor MA, Park J, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med 2004;116:223-229.
19. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-719.
20. Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004;63:127-134.
21. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002;25: 517-523.
22. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-741.
23. Miller CD, Phillips L, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161:1653-1659.
24. Brandle M, Zhou H, Smith BRK, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-2304.
25. Selby JV, Ray GT Zhang D, et al. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997;20:1396-1402.
26. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002,25:476-481.
27. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic Costs of Diabetes in the US in 2002. Diabetes Care 2003;26:917-932.
28. Grossman LD. New solutions for type 2 diabetes mellitus: The role of pioglitazone. Pharmacoeconomics 2002: 20(suppl 1):1-9.
29. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone ClinicalTrial In macroVascular Events): A randomised controlled trial. Lancet 2005;266:1279-1289.
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.